Hancock Jaffe Laboratories Inc (HJLI)
NASDAQ
6.75
+0.0050 (+0.07%)
Closed
Oct 28, 2026
Day's Range
6.717.20
52 wk Range
0.301113.79
Financial Statements - HJLI - Hancock Jaffe Laboratories Inc
Revenue
0▼ 100.0%
Net Income
-9.74M▼ 27.8%
EBITDA
-8.96M▼ 35.0%
Free Cash Flow
-7.80M▼ 29.9%
Income Statement
| Period Ending | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|
| Sales | 0 | 31.24K | 186.55K | 422.11K |
| Cost of Goods | - | - | 0 | 419.65K |
| Gross Profit | - | - | 186.55K | 2.45K |
 Operating Expense | - | - | - | - |
| Operating Income | -9.13M | -7.08M | -7.53M | -6.10M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | -4.09K | -588.82K | 1.35M | 231.41K |
| Pre Tax Income | -9.13M | -7.62M | -13.04M | -7.79M |
| Income Tax | - | - | - | - |
| Net Income | -9.74M | -7.62M | -16.35M | -8.25M |
| EPS Basic | -7.54 | -12 | -43.75 | -18.8 |
| EPS Diluted | -7.54 | -12 | -43.75 | -18.8 |
| Basic Shares Outstanding | 1.29M | 630.41K | 374.49K | 438.71K |
| Diluted Shares Outstanding | 1.29M | 630.41K | 374.49K | 438.71K |
| Ebit | - | - | - | - |
| Ebitda | -8.96M | -6.63M | -7.40M | -7.67M |
| Net Income Continuous Operations | - | - | - | - |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
